{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+sequence+1&page=2", "query": { "intervention": "Vaccine sequence 1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+sequence+1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T03:31:24.773Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02788045", "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 201, "start_date": "2016-07-08", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788045" }, { "nct_id": "NCT01856920", "title": "QUILT-3.006 for Recurrent Medullary Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medullary Thyroid Cancer (MTC)" ], "interventions": [ { "name": "GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NantCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 35, "start_date": "2013-03-26", "completion_date": "2018-05-08", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01856920" }, { "nct_id": "NCT07675629", "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))", "type": "BIOLOGICAL" }, { "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))", "type": "BIOLOGICAL" }, { "name": "Alhydrogel adjuvant", "type": "BIOLOGICAL" }, { "name": "GLA-SE adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Worcester HIV Vaccine", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 126, "start_date": "2026-09-01", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675629" }, { "nct_id": "NCT00499083", "title": "Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "aromatase inhibition therapy", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "19 Years to 120 Years · Female only" }, "enrollment_count": 17, "start_date": "2006-05-01", "completion_date": "2010-01-28", "has_results": true, "last_update_posted_date": "2023-09-29", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 2, "location_summary": "Tampa, Florida • Omaha, Nebraska", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499083" }, { "nct_id": "NCT03122223", "title": "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC-HIV (vCP2438)", "type": "BIOLOGICAL" }, { "name": "Bivalent subtype C gp120/MF59", "type": "BIOLOGICAL" }, { "name": "Bivalent subtype C gp120/AS01(B)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 160, "start_date": "2018-01-16", "completion_date": "2020-07-30", "has_results": true, "last_update_posted_date": "2023-03-14", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 9, "location_summary": "San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03122223" }, { "nct_id": "NCT02079701", "title": "Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pneumonia", "Acute Respiratory Disease" ], "interventions": [ { "name": "23-valent pneumococcal vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Naval Health Research Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 152723, "start_date": "2000-10", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2014-03-06", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 5, "location_summary": "San Diego, California • Great Lakes, Illinois • Fort Leonard Wood, Missouri + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Great Lakes", "state": "Illinois" }, { "city": "Fort Leonard Wood", "state": "Missouri" }, { "city": "Fort Jackson", "state": "South Carolina" }, { "city": "Parris Island", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02079701" }, { "nct_id": "NCT02860650", "title": "A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Filo", "type": "BIOLOGICAL" }, { "name": "MVA-BN-Filo", "type": "BIOLOGICAL" }, { "name": "Ad26.ZEBOV", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 72, "start_date": "2016-08", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02860650" }, { "nct_id": "NCT04019444", "title": "Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rabies", "Rabies Immunisation" ], "interventions": [ { "name": "ChAd155-RG", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Rabies Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 50, "start_date": "2019-09-19", "completion_date": "2023-03-24", "has_results": true, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 1, "location_summary": "Decatur, Georgia", "locations": [ { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019444" }, { "nct_id": "NCT03532217", "title": "Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Neoantigen DNA vaccine", "type": "BIOLOGICAL" }, { "name": "TriGrid Delivery System", "type": "DEVICE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "Peripheral blood", "type": "PROCEDURE" }, { "name": "Fecal samples", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2018-09-14", "completion_date": "2022-07-25", "has_results": false, "last_update_posted_date": "2022-08-05", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532217" }, { "nct_id": "NCT00075569", "title": "SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Precancerous Condition" ], "interventions": [ { "name": "HspE7", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 64, "start_date": "2004-03", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2018-05-21", "last_synced_at": "2026-09-28T03:31:24.773Z", "location_count": 2, "location_summary": "New York, New York • The Bronx, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075569" } ] }